Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 1243-1248

  Wang, X ^a   Tangjitgamol, S ^a   Liu, J ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hormonal therapy; Letrozole; Uterine sarcoma

Indexed keywords

LETROZOLE;

ABDOMINAL HYSTERECTOMY; ABDOMINAL SCINTISCANNING; AGED; ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL; RECURRENT DISEASE; RETROPERITONEAL TUMOR; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; UTERUS SARCOMA; UTERUS TUMOR;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIXED TUMOR, MULLERIAN; NEOPLASM RECURRENCE, LOCAL; NITRILES; RADIOTHERAPY, ADJUVANT; TRIAZOLES; UTERINE NEOPLASMS;

EID: 30944433966     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00193.x     Document Type: Article

References (36)

1. Chauveinc L, Deniaud E, Plancher C et al. Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 1999;72:232-7.
2. Papadopoulos AJ, Kenney A. Solid malignant uterine tumors. Curr Opin Obstet Gynecol 2001;11:296-301.
3. Livi L, Paiar F, Shah N et al. Uterine sarcoma: twenty-seven years of experience, Int J Radiat Oncol Biol Phys 2003;57:1366-73.
4. Riddle PJ, Echeta CB, Manek S et al. Retrospective study of management of uterine sarcomas at Oxford 1990-1998: role of adjuvant treatment. Clin Oncol (R Coll Radiol) 2002;14:54-61.
5. Schwarte SM, Weiss NS, Daling JR et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996;77:717-24.
6. Zelmanowicz A, Hildesheim A, Sherman M et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253-7.
7. Altaras MM, Jaffe R, Cohen I et al. Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: two cases and a review of the literature. Gynecol Oncol 1990;38:273-7.
8. Saga Y, Ohwada M, Kohno T et al. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer 2003;13:690-2.
9. Wickerham DL, Fisher B, Wolmark N et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.
10. Gonzalez-Bosquet E, Martinez-Palones JM, Gonzalez-Bosquet J et al. Uterine sarcoma: a clinicopathological study of 93 cases. Eur J Gynaecol Oncol 1997;18:192-5.
11. El Husseiny G, Al Bareedy N, Mourad WA et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol 2002; 25:256-60.
12. Piura B, Rabinovich A, Yanai-Inbar I et al. Uterine sarcoma in the south of Israel: study of 36 cases. J Surg Oncol 1997;64:55-62.
13. Amant F, Dreyer L, Makin J et al. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. Eur J Gynaecol Oncol 2001;22:194-200.
14. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-5.
15. Curtis RE, Freedman DM, Serman ME et al. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:70-4.
16. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832-3.
17. McCluggage WG, Abdulkader M, Price JH et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000;10:280-4.
18. Kloos I, Delaloge S, Pautier P et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 2002;12:496-500.
19. Fotiou S, Hatjieleftheriou G, Kyrousis G et al. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res 2000;20:2015-20.
20. Hoffmann W, Schmandt S, Kortmann RD et al. Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases. Gynecol Obstet Invest 1996;42:49-57.
21. Tinkler SD, Cowie VJ. Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992. Br J Radiol 1993;66:998-1001.
22. Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702-9.
23. Sabini G, Chumas JC, Mann WJ. Steroid hormone receptors in endometrial stromal sarcomas: a biochemical and immunohistochemical study. Am J Clin Pathol 1992;97:381-6.
24. Amant F, Gabriel C, Moerman P et al. Immunohistochemical determination of hormone receptors in uterine adenosarcomas. Gynecol Oncol 2003;88:463-4.
25. Ansink AC, Cross PA, Scorer P et al. The hormonal receptor status of uterine carcinosarcomas (mixed mullerian tumours): an immunohistochemical study. J Clin Pathol 1997;50:328-31.
26. Haynes BP, Dowsett M, Miller WR et al. The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003;87:35-45.
27. Miller WR, Anderson TJ, Dixon JM. Anti-tumor effects of letrozole. Cancer Invest 2002;20(Suppl. 2):15-21.
28. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003;9:468-72S.
29. Dowsett M, Jones A, Johnston SR et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
30. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93-102.
31. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-61.
32. Marty M, Gershanovich M, Campers B. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens. Proc ASCO 1997;16:156-64.
33. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
34. Amant F, Lottering ML, Joubert A et al. 2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecol Oncol 2003;91:299-308.
35. Spano JP, Soria JC, Kambouchner M et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 2003;20:87-93.
36. Maluf FC, Sabbatini P, Schwartz L et al. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 2001;82:384-8.